Poly-ICLC Dosing Regimen for Interferon Induction and Toxicity Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The clinical translation of double-stranded ribonucleic acids (dsRNAs) and poly-ICLC has been hindered by dosage, administration schedule, toxicity, and host species factors, with high doses being toxic and ineffective, while low doses show promise but require optimized administration regimens to maximize biological activity and minimize toxicity.
Innovation Solution
A method involving the administration of poly-ICLC in moderate doses (10 to 100 mcg/kg) spaced 4-72 hours apart, with the first dose given with or at the time of vaccine administration, and subsequent doses alone to stimulate interferon and enzyme activation, optimizing immune modulation and antiviral effects, and potentially administered every 2-3 days for chronic conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If high doses of poly-ICLC are administered to induce interferon, then interferon production is enhanced, but toxicity increases and clinical effectiveness decreases
Solution Approach 1:
The patent applies periodic action by administering poly-ICLC in multiple divided doses spaced 4-72 hours apart, rather than a single high dose. This periodic administration allows the immune system to respond to each dose while recovering from previous administrations, maintaining interferon induction effectiveness while avoiding the toxicity associated with high single doses. The regimen typically involves 2-5 doses over several days to weeks.
Solution Approach 2:
The patent segments the total poly-ICLC dosage into multiple smaller administrations. Instead of giving one large dose, the total amount is divided into several smaller doses given at intervals. This segmentation reduces peak concentration-related toxicity while maintaining cumulative immunomodulatory effects, as the immune system can process and respond to each smaller dose more effectively.
2Reliability
If poly-ICLC is administered to activate immune response, then antiviral and antiproliferative effects are enhanced, but treatment duration and complexity increase
Solution Approach 1:
The patent applies preliminary action by administering poly-ICLC doses in advance of actual viral infection or in the early stages of disease. The first dose is given with or at the time of vaccine administration to prime the immune system before the pathogen fully establishes infection. This preliminary immune activation creates a more robust and faster response when the actual threat occurs, reducing the need for prolonged treatment.
Solution Approach 2:
The patent maintains continuity of useful action through a structured dosing schedule that ensures continuous immune system stimulation. Doses are administered at intervals of 4-72 hours to maintain adequate drug levels and持续 immune activation. This continuous action ensures that the immune system remains engaged and effective throughout the treatment period, achieving reliable therapeutic outcomes without excessive treatment duration.
3Reliability
If poly-ICLC is given with vaccine to enhance adjuvant effect, then immune response to vaccine is improved, but timing and scheduling complexity increases
Solution Approach 1:
The patent merges the administration of poly-ICLC with vaccine delivery by giving the first poly-ICLC dose with or at the time of vaccine administration. This combination approach leverages the adjuvant effect of poly-ICLC to enhance the immune response to the vaccine antigen in a single administration event. Subsequent poly-ICLC doses are given alone to maintain immune activation, simplifying the overall schedule compared to completely separate administrations.
Solution Approach 2:
The patent uses poly-ICLC as an intermediary substance that mediates between the vaccine antigen and the immune system. Poly-ICLC acts as an adjuvant that enhances the immunogenicity of the vaccine by stimulating innate immune pathways, which in turn improves the adaptive immune response to the vaccine antigen. This intermediary role allows for coordinated administration that simplifies scheduling while maximizing immunological benefits.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances immune responses, reduces toxicity, and achieves prolonged therapeutic benefits in treating viral, neoplastic, and autoimmune diseases, including viral infections and cancers, by maximizing interferon and enzyme induction, and maintaining immune activation over time.
Implementation Method 1
administered in a moderate dose (10 to 100 mcg/kg) sufficient to induce a 'natural mix' of interferons, cytokines, chemokines, costimulatory molecules, enzymes such as OAS and PKR
Implementation Method 2
subsequent doses alone to stimulate or disinhibit the induced enzymes such as OAS and PKR
Implementation Method 3
PRR such as TLR3, and other regulatory molecules such as p56; and the subsequent doses are administered alone to stimulate or disinhibit the induced enzymes
Implementation Method 4
to modulate the immune system for treatment of certain neoplastic, infectious and autoimmune conditions
Data Source
AI summary
An improved understanding and method for the clinical adjuvant and immunomodulatory use of dsRNAs and ply-ICLC in particular, alone or in conjunction with other drugs and various vaccines designed to prevent or treat various microbial, viral, neoplastic, autoimmune diseases, and or degenerative diseases.